Genentech, Inc.

F. Hoffmann-la Roche Ag

Baihua Hu

Matthew Volgraf

Vishal Verma

Aijun Lu

Anthony A Estrada

Daniel Shore

Joseph P Lyssikatos

Andrew Madin

Bryan K Chan

Huifen Chen

Jun Liang

Lewis J Gazzard

BinQing Wei

Timothy Heffron

Michael Siu

Graham Elgin Jones

Sushant Malhotra

Emanuela Gancia

Michael Lainchbury

Weiru Wang

Elisia Villemure

Craig Stivala

Rohan V Mendonca

Kin Chiu Fong

Aihe Zhou

Naomi S Rajapaksa

Guosheng Wu

Joy Drobnick

Yonghan Hu

Malcolm Huestis

Blake Daniels

Matthew W Cartwright

John Tellis

Andrew Good

David Favor

Po-wai Yuen

Steven Huy Do

Aleksandr Kolesnikov

Steven T Staben

Jianwen A Feng

Georgette M Castanedo

Po-Wai Yuen

Andrew Peter Cridland

Nicole Blaquiere

Lan Wang

Stuart Ward

Jason Burch

Binqing Wei

Robin Larouche-Gauthier

Francis Beaumier

Martin Dery

Xingyu Lin

Yanyan Chu

Naomi Rajapaksa

Andrew Cridland

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Naphthyridines as inhibitors of HPK1

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.

Oxadiazolones as transient receptor potential channel inhibitors

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Sulfonylcycloalkyl carboxamide compounds

The invention provides compounds of formula I: and pharmaceutically acceptable salts thereof where Ris a substituted or unsubstituted phenyl or a fused bicyclic comprising a substituted or unsubstituted phenyl. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Sulfonyl pyridyl TRP inhibitors

The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

Substituted sulfonamide compounds

The invention relates to compounds of Formula (0): 

Alkynyl alcohols and methods of use

Growing community of inventors

Beijing, China

Baihua Hu